- Home
- MP vs RYTM Comparison
MP vs RYTM Comparison
Compare MP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MP
- RYTM
- Stock Information
- Founded
- MP 2017
- RYTM 2008
- Country
- MP United States
- RYTM United States
- Employees
- MP N/A
- RYTM N/A
- Industry
- MP Metal Mining
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- MP Basic Materials
- RYTM Health Care
- Exchange
- MP Nasdaq
- RYTM Nasdaq
- Market Cap
- MP 4.0B
- RYTM 3.8B
- IPO Year
- MP N/A
- RYTM 2017
- Fundamental
- Price
- MP $21.80
- RYTM $61.33
- Analyst Decision
- MP Buy
- RYTM Strong Buy
- Analyst Count
- MP 9
- RYTM 12
- Target Price
- MP $23.61
- RYTM $76.75
- AVG Volume (30 Days)
- MP 5.9M
- RYTM 632.6K
- Earning Date
- MP 05-08-2025
- RYTM 05-07-2025
- Dividend Yield
- MP N/A
- RYTM N/A
- EPS Growth
- MP N/A
- RYTM N/A
- EPS
- MP N/A
- RYTM N/A
- Revenue
- MP $215,981,000.00
- RYTM $136,863,000.00
- Revenue This Year
- MP $44.19
- RYTM $37.88
- Revenue Next Year
- MP $70.76
- RYTM $72.84
- P/E Ratio
- MP N/A
- RYTM N/A
- Revenue Growth
- MP 4.63
- RYTM 48.88
- 52 Week Low
- MP $10.02
- RYTM $35.35
- 52 Week High
- MP $29.72
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- MP 50.05
- RYTM 51.78
- Support Level
- MP $18.64
- RYTM $58.72
- Resistance Level
- MP $20.77
- RYTM $63.24
- Average True Range (ATR)
- MP 1.15
- RYTM 2.43
- MACD
- MP 0.03
- RYTM -0.15
- Stochastic Oscillator
- MP 80.20
- RYTM 65.51
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.